MyFinsight
Home
Blog
About
Back
Cash Flow
AEON Biopharma, Inc. (AEON)
AEON Biopharma, Inc. (AEON)
source: myfinsight.com
Proceeds from issuance of
at-the-market shares, net
$886K
(954.76%↑ Y/Y)
Net cash provided by
financing activities
$886K
(-95.19%↓ Y/Y)
Net increase in cash
-$2,812K
(-133.37%↓ Y/Y)
Canceled cashflow
$886K
Stock-based compensation
expense
$1,659K
(-49.89%↓ Y/Y)
Accounts payable
$1,216K
(160.71%↑ Y/Y)
Change in fair value of
convertible notes
-$213K
(93.89%↑ Y/Y)
Other assets and
liabilities
-$21K
(-400.00%↓ Y/Y)
Depreciation
$20K
(-48.72%↓ Y/Y)
Net cash used in
operating activities
-$3,698K
(63.02%↑ Y/Y)
Canceled cashflow
$3,129K
Change in fair value of
warrants
-$4,941K
(94.27%↑ Y/Y)
Net (loss) income
-$1,155K
(-147.09%↓ Y/Y)
Accrued expenses and
other liabilities
-$541K
(82.07%↑ Y/Y)
Prepaid expenses and
other current assets
$179K
(-26.94%↓ Y/Y)
Change in fair value of
contingent consideration
-$11K
(99.68%↑ Y/Y)
Back